Related Experiment Videos
Somatostatin receptor scintigraphy in gastrinomas
1Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1804, USA.
Italian Journal of Gastroenterology and Hepatology
|December 22, 1999
Summary
Somatostatin receptor scintigraphy is the preferred imaging method for Zollinger-Ellison syndrome, accurately detecting gastrinomas and metastases. While it guides management, it does not improve cure rates and can miss small tumors.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- The diagnostic utility of radiolabeled somatostatin analogues, specifically [111In-DTPA-DPhe1]octreotide, for imaging neuroendocrine tumors like carcinoid and pancreatic endocrine tumors is recognized.
- However, its superiority over conventional imaging modalities and its specific role in patient management remain unclear.
Purpose of the Study:
- To review five National Institutes of Health studies on Zollinger-Ellison syndrome patients to define the role of somatostatin receptor scintigraphy.
- To compare its efficacy against conventional imaging techniques for tumor detection and management.
Main Methods:
- Study 1: Assessed sensitivity of somatostatin receptor scintigraphy versus conventional studies in 80 patients.
- Study 2: Determined the impact of somatostatin receptor scintigraphy on management in 122 patients.
- Study 3: Evaluated differentiation of small liver metastases from hemangiomas using somatostatin receptor scintigraphy and conventional methods in 29 patients.
- Study 4: Compared somatostatin receptor scintigraphy, MRI, and bone scanning for bone metastases in 115 patients.
- Study 5: Analyzed the detection of surgically found gastrinomas by somatostatin receptor scintigraphy in 35 patients and its effect on cure rates.
Main Results:
- Somatostatin receptor scintigraphy demonstrated superior sensitivity for detecting primary or metastatic gastrinomas.
- It influenced patient management in 47% of cases and was the sole method capable of distinguishing small liver metastases from hemangiomas.
- Somatostatin receptor scintigraphy and MRI showed higher sensitivity for bone metastases than bone scanning.
- However, it missed 33% of surgically detected gastrinomas, particularly small duodenal tumors, and did not improve cure rates.
Conclusions:
- Somatostatin receptor scintigraphy is the imaging method of choice for Zollinger-Ellison syndrome, aiding preoperative localization, metastasis detection, and differentiating small liver lesions.
- Its specificity is high, though not extensively studied, as is its use with endoscopic ultrasound.
- Findings are likely applicable to other neuroendocrine tumors, excluding insulinomas.